

Supplementary Table S2. Exclusion criteria

SL/NO	Title	Reason
1.	Functional improvement in a person with tetraplegia after chemodenervation and motor retraining	Conference Abstract
2.	A 10-year retrospective review of lower limb botulinum toxin injection for spasticity	Conference Abstract
3.	Botulinum toxin A (BoNT A) treatment of postsurgical/posttraumatic focal movements not responding to oral therapy	Conference Abstract
4.	Burden of spasticity among patients and caregivers: Results of a multinational survey	Conference Abstract
5.	Rhomboid/levator scapulae spasticity after incomplete cervical spinal cord injury treated with botulinum toxin type A: A case report	Conference Abstract
6.	Spasticity-related pain treated with botulinum toxin	Conference Abstract
7.	Delivery of botulinum toxin for the management of spasticity: Twenty-two cases	Conference Abstract
8.	Evaluation of health utility in patients receiving onabotulinumtoxinA (Botox [®]) for the treatment of adult focal spasticity: Results from Mobility [®] , a prospective observational cohort study	Conference Abstract
9.	Comparison of onabotulinumtoxinA utilization and effectiveness across various etiologies of spasticity from the adult spasticity international registry study: ASPIRE	Conference Abstract
10.	Comparison of onabotulinumtoxinA utilization and effectiveness across various etiologies of spasticity from the adult spasticity international registry study: ASPIRE	Conference Abstract
11.	Baseline demographics and clinical characteristics of patients treated for spasticity in the adult spasticity international registry (aspire study)	Conference Abstract
12.	The adult spasticity international registry (aspire study): Baseline demographics and clinical characteristics of patients treated for spasticity	Conference Abstract
13.	OnabotulinumtoxinA treatment utilization varies by etiology of spasticity, while maintaining high patient and clinician satisfaction: results from the aspire study	Conference Abstract
14.	Botulinum neurotoxin type A for simultaneous multiple indications in neurologic patients	Conference Abstract
15.	A multi-year experience with phenol neurolysis for spasticity management: Practice pattern and clinical outcomes	Conference Abstract
16.	Spasticity and goal attainment scale characteristics in individuals receiving botulinum toxin type-A injections	Conference Abstract
17.	Ultrasound-guided onabotulinum toxin A (Botox) injection of the psoas muscle using a posterior approach: A case report	Conference Abstract
18.	Botulinum toxin type A for the treatment of muscle contractures secondary to acute spinal cord injury in a young cat	Conference Abstract
19.	AbobotulinumtoxinA (Dysport [®]) shows higher efficacy and longer duration of action in rats with spinal cord injury-mediated spasticity than in healthy controls	Conference Abstract
20.	The impact of orthopedic intervention on gait: A case study	Conference Abstract
21.	Impact of spasticity in the development of neurological heterotopic ossifications (NHOs): Injection of botulinum toxin in a mouse model developing NHOs	Conference Abstract
22.	Adverse event profile of high (>600 units) vs lower dose botulinum toxin	Conference Abstract
23.	Experience of physical medicine and rehabilitation department: Treatment of spasticity by botulinum toxin injection, about 30 cases	Conference Abstract
24.	Fewer injections of botulinum toxin type A for treatment of spasticity is perceived as beneficial by both patients and caregivers	Conference Abstract
25.	A comparison of onabotulinumtoxinA (BOTOX) dosing patterns and health utility in stroke vs. other etiologies of adult focal spasticity in canada: MOBILITY-a prospective observational cohort study	Conference Abstract
26.	Baseline characteristics and botulinum toxin type A (BONTA) dosing patterns for patients with adult focal spasticity in a prospective observational cohort study: Mobility	Conference Abstract
27.	Health utility among patients with adult focal spasticity treated with botulinum toxin type A (BONTA) in a prospective observational cohort study: Mobility	Conference Abstract
28.	Effects of botulinum toxin type A combined with exercise on the functional recovery after spinal cord injury	Conference Abstract
29.	Kinesiological benefits of botulinum toxin type A combined with exercise on the functional recovery after spinal cord injury	Conference Abstract
30.	Clinical research of electroacupuncture combined with acupoint-injection of botulinum toxin A in treating the muscle spasticity by spinal cord injury	Foreign language
31.	Optimized therapy of spastic syndrome by combination intrathecal baclofen with botulinum toxin	Foreign language
32.	Preclinical models of muscle spasticity: valuable tools in the development of novel treatment for neurological diseases and conditions	Review
33.	Latest approaches for the treatment of spasticity and autonomic dysreflexia in chronic spinal cord injury	Review
34.	Latest approaches for the treatment of spasticity and autonomic dysreflexia in chronic spinal cord injury	Review
35.	The evaluation and treatment of elbow dysfunction secondary to spasticity and paralysis	Review
36.	Botulinum toxin and spinal cord injury	Review

SL/NO	Title	Reason
37.	Ultrasound Guidance for Botulinum Neurotoxin Chemodenervation Procedures	Review
38.	Spinal cord injury and use of botulinum toxin in reducing spasticity	Review
39.	Special Considerations in Assessing and Treating Spasticity in Spinal Cord Injury	Review
40.	The use of botulinum toxin for spasticity after spinal cord injury	Unavailable
41.	Relationship Between Botulinum Toxin, Spasticity, and Pain: a Survey of Patient Perception	Irrelevant population
42.	Patient Perspectives on the Therapeutic Profile of Botulinum Neurotoxin Type A in Spasticity	Irrelevant population
43.	High clinician- and patient-reported satisfaction with individualized onabotulinumtoxinA treatment for spasticity across several etiologies from the ASPIRE study	Irrelevant population
44.	The effect of botulinum toxin and phenol injections on lower extremity spasticity in spinal cord injury	Unavailable
45.	Botulin toxin for spasticity in spinal cord damage	Unavailable
46.	Effect of intrathecal baclofen, botulinum toxin type A and a rehabilitation programme on locomotor function after spinal cord injury: a case report	Combined therapy